People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Octave Bioscience Inc | — | Biotech | Series B | $105.8M | $169.5M | 2025 |
Doug Biehn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Doug Biehn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brook Byers | 1 | 13 |
| Andrea Jackson | 1 | 6 |
| Thomas Hawes | 1 | 6 |
| William Hagstrom | 1 | 4 |
| Mark Weeks | 1 | 4 |
| George Scangos | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Lucy Coassin | 1 | 2 |
| Marcel Konrad | 1 | 1 |
| Melinda Thomas | 1 | 1 |
| A. Grant Heidrich III | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.